Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Launched by DANA-FARBER CANCER INSTITUTE · Mar 26, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The Tools for Reducing Inequity in Acute Leukemia (TRIAL) study is testing a new web-based application designed to help people diagnosed with acute leukemia. This application provides important information and resources about leukemia and how to participate in clinical trials, which are research studies that help find better treatments. The goal of the trial is to see how effective this tool can be in supporting patients during their treatment journey.
To be eligible for this study, participants need to be 18 years or older, speak English, and be suspected of having acute leukemia. They must also be admitted to a specific hospital unit for treatment. Participants should be able to understand and sign a consent form, which means they agree to take part in the study. Those with serious cognitive issues that prevent them from participating, or those who have already taken part in earlier testing of the application, will not be included. If you join, you can expect to help test the application in person and provide feedback on its usefulness. This is an important step in ensuring that patients have the tools they need to navigate their diagnosis and treatment effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 or older
- • English speaking
- • Ability to understand and willingness to sign written informed consent
- • Clinical suspicion of acute leukemia
- • Admitted to DFCI-affiliated inpatient unit
- Exclusion Criteria:
- • Cognitive impairment rendering the individual unable to participate in beta testing
- • This will be assessed by focused chart review and consultation with the patients' inpatient care team.
- • The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \<18 years old), prisoners.
- • Inability to participate in in-person application testing.
- • Patients who participated in alpha-testing through protocol 23-404 (Appendix A)
About Dana Farber Cancer Institute
The Dana-Farber Cancer Institute is a premier cancer research and treatment institution located in Boston, Massachusetts. Renowned for its commitment to advancing cancer care through innovative research, the institute integrates cutting-edge clinical trials with a multidisciplinary approach to patient care. With a focus on translating scientific discoveries into effective therapies, Dana-Farber collaborates with a network of leading researchers and healthcare professionals to improve outcomes for patients with cancer. The institute’s dedication to education, advocacy, and community engagement further underscores its mission to eradicate cancer and enhance the quality of life for those affected by the disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Andrew Hantel, MD
Principal Investigator
Dana-Farber Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported